License Agreement with Allogene Therapeutics

March 24, 2020 11:00 AM EDT

Released : March 24, 2020 07:00

RNS Number : 2942H
MaxCyte, Inc.
24 March 2020

FOR IMMEDIATE RELEASE

MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement

- Agreement enables Allogene, a pioneer in the development of AlloCAR T™ therapies for cancer, to utilize MaxCyte's ExPERT™ platform in target candidates

GAITHERSBURG, MD, and SOUTH SAN FRANCISCO, CA, 24 March 2020 - MaxCyte, Inc., (LSE: MXCT), a global cell-based therapies and life sciences company, and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced a clinical and commercial license agreement. Under the terms of the agreement, Allogene gains rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to develop and advance its AlloCAR T™ candidates through to commercialization. In return, MaxCyte will receive undisclosed development, approval and commercial milestones in addition to other licensing fees. The first two Allogene investigational therapies intended to utilize this validated gene editing and advanced proprietary cell manufacturing technology are directed at CD19 and BCMA targets.

MaxCyte's ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next

wave of biological and cellular therapeutics. Allogene intends to deploy the MaxCyte technology to effect the gene editing steps during the production process. The closed system and high efficiency make it an ideal addition for GMP operations.

"MaxCyte's ExPERT platform has become the industry standard in electroporation technology and allows us to increase efficiency and improve yield, which is a critical component to the value proposition of our AlloCAR T™ therapies," said Alison Moore, Ph.D., Chief Technical Officer of Allogene.

Doug Doerfler, President & CEO of MaxCyte, said: "We're honored to partner with Allogene to help unlock the full potential of its next-generation allogeneic CAR T therapies through utilization of our Flow Electroporation® technology and ExPERT™ platform."

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte biopharmaceutical partners leverage the Company's Flow Electroporation® Technology to advance the development of innovative, transformative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 100 partnered programme licenses in cell therapy with more than 70 licensed for clinical use. The Company has now entered into nine clinical/commercial license partnerships with leading cell therapy developers and the potential pre-commercial milestones from these relationships now significantly exceeds $650 million. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their therapeutic products. MaxCyte is also developing novel CARMA therapies, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. MaxCyte has established CARMA Cell Therapies as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform. For more information, visit www.maxcyte.com.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of "off-the-shelf" CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press

release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability of the MaxCyte technology and platform to increase efficiency and improve yield of AlloCAR T™ therapies, the ability to manufacture AlloCAR T™ therapies, the ability to progress AlloCAR T therapies through clinical trials and obtain regulatory approval, and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-K for the year ended December 31, 2019. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

AlloCAR TÔ is a trademark of Allogene Therapeutics, Inc.

MaxCyte Contacts:

MaxCyte Inc. +1 301 944 1660
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer

Nominated Adviser and Joint Corporate Broker
Panmure Gordon +44 (0)20 7886 2500
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns

Joint Corporate Broker
Numis Securities Limited +44 (0)20 7260 1000
James Black
Duncan Monteith

Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-com
Chris Welsh
Sukaina Virji

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

END

AGRPPUMGWUPUPGW